启迪药业(000590) - 2016 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2016 was ¥93,432,185.87, representing a 6.07% increase compared to ¥88,082,877.49 in the same period last year[8] - Net profit attributable to shareholders for Q1 2016 was ¥13,488,156.46, a 31.49% increase from ¥10,257,697.97 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥13,472,788.07, reflecting a 32.76% increase from ¥10,148,098.29 year-on-year[8] - The basic earnings per share for Q1 2016 was ¥0.0604, up 31.59% from ¥0.0459 in the same quarter last year[8] - The company's net profit for the current period is CNY 13,488,156.46, representing a 31.49% increase compared to the previous period's net profit of CNY 10,257,697.97[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥599,683,262.06, a 2.09% increase from ¥587,434,583.60 at the end of the previous year[8] - The net assets attributable to shareholders at the end of the reporting period were ¥219,282,559.73, which is a 6.55% increase from ¥205,794,093.22 at the end of the previous year[8] - Accounts receivable decreased by 39.31%, from CNY 12,112,971.07 to CNY 7,351,565.10, due to the recovery of some receivables during the reporting period[1] - The amount of other receivables increased by 95.32%, from CNY 1,788,321.17 to CNY 3,493,022.65, attributed to an increase in transaction amounts[1] - The company's construction in progress rose by 56.54%, from CNY 5,530,794.08 to CNY 8,657,974.28, due to the investment in a new oral liquid project[1] - Prepayments increased by 39.35%, from CNY 87,019,786.66 to CNY 121,258,081.86, indicating a rise in advance payments received[1] Cash Flow - The net cash flow from operating activities for Q1 2016 was ¥1,296,137.03, a significant recovery from a negative cash flow of ¥12,599,486.08 in the same period last year[8] - Cash received from operating activities increased by 55.06%, from CNY 1,827,876.86 to CNY 2,834,323.80, mainly due to the receipt of bid guarantees[17] - Cash paid to employees increased by 57.19%, from CNY 28,737,252.14 to CNY 45,173,214.36, primarily due to higher social insurance payments[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,074[11] - The top shareholder, Tsinghua Tongfang Co., Ltd., held 18.61% of the shares, amounting to 41,561,800 shares[11] Strategic Initiatives - The company successfully reversed the delisting risk warning on April 12, 2016, after achieving profitability in 2015[19] - The company plans to continue optimizing resource allocation and expanding its market for advantageous products to maintain profitability[19] - The company is in the process of a non-public stock issuance, which requires approval from the China Securities Regulatory Commission[20] Government Support - The company received government subsidies amounting to ¥68,493.00 during the reporting period[9]